Close Menu

NEW YORK (GenomeWeb) – Biocept reported after the close of the market on Monday that its second quarter revenues increased 45 percent year over year.

For the three months ended June 30, the San Diego-based liquid biopsy firm saw $1.2 million in revenues compared to the $822,238 it brought in during the same quarter last year.

According to the company, revenue growth reflects a shift in commercial efforts toward specific segments of the oncology market where Biocept believes its assays can help the most patients: prostate, breast, and lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.